Bristol Myers Squibb shares preliminary KarXT trial data
Bristol Myers Squibb (BMY) presented preliminary Phase 3 data from its ADEPT trials for KarXT in treating psychosis related to Alzheimer’s disease. The studies showed mean reductions in hallucinations and delusions, with adverse events reported. KarXT is FDA-approved for schizophrenia. No treatments are currently approved for Alzheimer’s-related psychosis.
How this was made
The 30-second read
Why it matters
The disclosed symptom-scale reductions and discontinuation rates provide early efficacy and tolerability signals, but the lack of unblinded double-blind treatment-period results keeps regulatory and commercial confidence incomplete.
Market read
Traders may adjust biotech risk exposure based on early read-through of efficacy and safety, while waiting for unblinded double-blind data to confirm signal strength.
What to watch
Adverse-event rates are high in both studies (56.6% and 65.1%), and the article notes ongoing trials and exclusion of participants still ongoing at cutoff, which can affect interpretability.
Background
KarXT (xanomeline plus trospium chloride) is FDA-approved as Cobenfy for schizophrenia; ADEPT Phase 3 program is evaluating it for psychosis associated with Alzheimer’s disease.
Ticker impact
Bristol Myers Squibb reported preliminary Phase 3 ADEPT open-label data for KarXT in Alzheimer’s-associated psychosis, including hallucination/delusion score reductions and adverse-event rates.
Likely modest upside bias as investors price in potential clinical benefit, tempered by the open-label nature and ongoing blinded double-blind data.
The article provides specific symptom-scale reductions and discontinuation/adverse-event percentages, which are decision-relevant for biotech trial read-through, but it explicitly excludes blinded double-blind outcomes and is labeled preliminary/descriptive.
Market effects
Strengthens the Alzheimer’s psychosis treatment pipeline narrative and may increase competitive attention on muscarinic-agonist approaches and trial endpoints.
Limited direct regional spillover; primarily impacts US-listed biotech sentiment around CNS and Alzheimer’s pipeline progress.
Conference-stage clinical updates can influence global biotech risk appetite for CNS assets, though final regulatory relevance depends on blinded efficacy data.
Counterpoint
Open-label, descriptive analyses can overstate benefit versus controlled data; investors may fade the move until double-blind results unblind.
Key entities
- companyBristol Myers Squibb
Sponsor of the ADEPT Phase 3 program evaluating KarXT for Alzheimer’s-associated psychosis.
- drugKarXT
Xanomeline plus trospium chloride; being studied for psychosis associated with Alzheimer’s disease.
- clinical_trialADEPT-1 and ADEPT-3
Open-label studies within the ADEPT clinical trial program; double-blind periods remain blinded.




